Solid Lipid Nanoparticles
Solid Lipid Nanoparticles - Related Videos
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
0 Views •
Cited by 12 •
2015
In this study, a method for synthesizing ultra-small populations of biocompatible nanoparticles was described, as well as several in vitro methods by which to assess their cellular interactions.
06:02
Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device
0 Views •
Cited by 14 •
2022
Microfluidic-based lipid nanoparticle (LNP) production methods have attracted attention in drug delivery systems (DDSs), including RNA delivery. This protocol describes the fabrication, LNP (siRNA-loaded LNP) production, and LNP evaluation processes using our original microfluidic device named iLiNP.
08:10
Synthesizing Lipid Nanoparticles by Turbulent Flow in Confined Impinging Jet Mixers
0 Views •
Cited by 21 •
2024
A detailed protocol for synthesizing lipid nanoparticles (LNPs) using confined impinging jet (CIJ) mixer technologies, including a two-jet CIJ and a four-jet multi-inlet vortex mixer (µMIVM), is demonstrated. The CIJ mixers generate reproducible, turbulent micro-mixing environments, resulting in the production of monodisperse LNPs.
08:55
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
0 Views •
Cited by 19 •
2023
Here, a protocol for formulating lipid nanoparticles (LNPs) that encapsulate mRNA encoding firefly luciferase is presented. These LNPs were tested for their potency in vitro in HepG2 cells and in vivo in C57BL/6 mice.
11:27
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
0 Views •
Cited by 1 •
2022
This publication shows the application of x-ray diffraction and differential scanning calorimetry as gold standards for investigating the solid-state of lipid-based excipients (LBEs). Understanding the solid-state alteration in LBEs and its effect on the performance of pharmaceutical products thereof is the key factor for manufacturing robust lipid-based dosage forms.
FAQs
The lipid matrix provides the structural environment for incorporating active compounds, particularly molecules with poor water solubility. Surfactants stabilize the resulting colloidal suspension and modify particle surface properties. Together, these components affect how much compound can be incorporated, how the particles behave in aqueous media, and how the active compound is released.
Maintaining the lipid matrix in a solid state at room or physiological temperature supports particle integrity during use. This state can help incorporate poorly water-soluble compounds while contributing to their stability and controlled release. Consequently, the physical state of the lipid is central to how the formulation protects and transports its active cargo.
Both composition and preparation conditions influence the key properties of Solid Lipid Nanoparticles. Changes in the lipid matrix or surfactant system can alter particle size, surface behavior, and the amount of compound incorporated. Preparation conditions also affect crystallinity and release behavior, so these variables must be considered together during formulation design.
A nanoparticle formulation can improve the aqueous dispersibility and stability of an active compound compared with the free molecule. The lipid matrix and stabilizing surfactants create a structured colloidal system that can also modify release. These changes are especially relevant for poorly water-soluble molecules whose handling and performance may be limited in free form.
Formulation development begins by selecting a lipid matrix capable of incorporating the active compound, then establishing a surfactant system that stabilizes the particle suspension. Researchers vary composition and preparation conditions to obtain a suitable colloidal formulation. The resulting material is evaluated for particle size, crystallinity, encapsulation efficiency, and release behavior.
They are useful when researchers need to formulate active compounds that are poorly water-soluble or require improved stability and aqueous dispersibility. The platform supports investigation of how lipid composition, surfactant choice, and preparation conditions affect delivery-related properties. It therefore serves both as a formulation strategy and as a system for studying structure-property relationships.
Evaluation should include particle size, crystallinity, encapsulation efficiency, and release behavior because these measurements describe different aspects of formulation performance. Particle size characterizes the colloidal system, crystallinity indicates the state of the lipid matrix, encapsulation efficiency measures compound incorporation, and release behavior shows how the formulation controls active-compound availability over time.